Healthcare - Biotechnology - NASDAQ - US
$ 363.25
-5.96 %
$ 16.2 B
Market Cap
15.97
P/E
INCOME STATEMENT
2.33 B
REVENUE
1.18 B
OPERATING INCOME
985 M
NET INCOME
EFFICIENCY
Earnings Waterfall
United Therapeutics Corporation
| Revenue | 2.33 B |
| Cost Of Revenue | 258 M |
| Gross Profit | 2.07 B |
| Operating Expenses | 885 M |
| Operating Income | 1.18 B |
| Other Expenses | 200 M |
| Net Income | 985 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | Dec-2011 | Dec-2010 | Dec-2009 | Dec-2008 | Dec-2007 | Dec-2006 | Dec-2005 | Dec-2004 | Dec-2003 | Dec-2002 | Dec-2001 | Dec-2000 | Dec-1999 | Dec-1998 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||||||||||||||||
| Revenue | 2 327.5 | 1 936.3 | 1 685.5 | 1 483.3 | 1 448.8 | 1 627.8 | 1 725.3 | 1 598.8 | 1 465.8 | 1 288.5 | 1 117.0 | 916.1 | 743.2 | 603.8 | 369.8 | 281.5 | 210.9 | 159.6 | 115.9 | 73.6 | 53.3 | 30.1 | 5.7 | 2.0 | 0.4 | 100 K |
| GROSS PROFIT | ||||||||||||||||||||||||||
| Cost Of Revenue | 257.5 | 146.7 | 122.5 | 108.1 | 117.6 | 198.7 | 105.7 | 72.7 | 69.0 | 125.9 | 131.1 | 119.3 | 88.9 | 73.5 | 45.3 | 30.1 | 22.3 | 17.0 | 12.3 | 8.2 | 6.8 | 5.5 | 3.1 | 1.7 | 1.4 | 0 |
| Gross Profit | 2 070.0 | 1 789.6 | 1 563.0 | 1 375.2 | 1 331.2 | 1 429.1 | 1 619.6 | 1 526.1 | 1 396.7 | 1 162.6 | 985.9 | 796.8 | 654.3 | 530.4 | 324.5 | 251.4 | 188.7 | 142.6 | 103.6 | 65.3 | 46.6 | 24.7 | 2.6 | 0.3 | (1.0) | 100 K |
| OPERATING INCOME | ||||||||||||||||||||||||||
| Operating Expenses | 885.1 | 809.9 | 1 007.1 | 781.6 | 1 518.8 | 623.7 | 594.7 | 464.4 | 697.7 | 623.8 | 693.4 | 375.1 | 336.5 | 366.4 | 298.5 | 333.5 | 182.4 | 113.6 | 60.7 | 52.1 | 58.1 | 42.7 | 49.5 | 81.8 | 34.4 | 13.4 |
| Selling, General and Administrative Expenses | 477.1 | 487.0 | 467.0 | 423.9 | 336.2 | 265.8 | 330.1 | 316.8 | 452.6 | 381.3 | 394.0 | 201.7 | 156.5 | 199.6 | 176.3 | 94.3 | 99.0 | 54.0 | 24.7 | 21.5 | 22.7 | 15.9 | 16.9 | 11.7 | 5.0 | 2.4 |
| Research and Development Expenses | 408.0 | 322.9 | 540.1 | 357.7 | 1 182.6 | 357.9 | 264.6 | 147.6 | 245.1 | 242.5 | 299.3 | 173.4 | 180.0 | 166.8 | 122.2 | 239.2 | 83.4 | 57.6 | 36.1 | 30.6 | 35.4 | 26.8 | 32.6 | 70.2 | 30.7 | 11.0 |
| Operating Income | 1 184.9 | 979.7 | 555.9 | 593.6 | (187.6) | 805.4 | 814.9 | 1 061.7 | 699.0 | 538.8 | 292.5 | 421.6 | 317.8 | 164.0 | 26.0 | (82.1) | 6.3 | 29.0 | 42.9 | 13.2 | (11.5) | (18.0) | (46.9) | (81.5) | (35.4) | (13.3) |
| PRE-TAX INCOME | ||||||||||||||||||||||||||
| Interest Income Expense | 59.3 | 32.4 | 18.6 | 23.5 | 44.2 | 13.9 | 9.0 | 3.9 | 4.7 | 17.6 | 18.1 | 16.6 | 21.4 | 19.7 | 12.9 | 16 K | 2.2 | 0.5 | 29 K | 4 K | 0.1 | 0.1 | 0.2 | 0.1 | 0 | 0 |
| Total Other Income | 89.4 | (29.1) | 38.0 | 45.3 | 22.6 | (46.5) | (45.4) | (1.5) | 345.4 | (13.6) | (13.6) | 19.0 | (18.7) | (16.2) | (7.2) | 9.8 | 10.3 | 10.9 | 4.6 | 2.2 | 1.6 | (5.6) | 9.7 | (4.7) | 63.5 K | 0.5 |
| Pre-Tax Income | 1 274.3 | 950.6 | 593.9 | 638.9 | (165.0) | 758.9 | 769.5 | 1 060.2 | 1 044.4 | 525.2 | 278.9 | 440.7 | 299.1 | 147.8 | 18.8 | (72.3) | 16.6 | 39.9 | 47.5 | 15.4 | (10.0) | (23.7) | (37.3) | (86.2) | (35.3) | (12.8) |
| NET INCOME | ||||||||||||||||||||||||||
| Tax Provision | 289.5 | 223.3 | 118.1 | 124.1 | (60.5) | 169.7 | 351.6 | 346.5 | 392.8 | 185.1 | 104.3 | 136.2 | 81.9 | 41.9 | (0.7) | (29.5) | (3.3) | (34.1) | (17.5) | (3.0) | (2.5) | 5.4 | (9.7) | (5.9) | (1.9) | 0 |
| Net Income | 984.8 | 727.3 | 475.8 | 514.8 | (104.5) | 589.2 | 417.9 | 713.7 | 651.6 | 340.1 | 174.6 | 304.4 | 217.9 | 105.9 | 19.5 | (42.8) | 19.9 | 74.0 | 65.0 | 15.4 | (10.0) | (23.7) | (37.3) | (75.6) | (33.5) | (12.8) |
| EPS | 21 | 16 | 10.6 | 11.7 | 2.39 | 13.5 | 9.5 | 16.3 | 14.2 | 7.06 | 3.49 | 5.84 | 3.81 | 1.89 | 0.37 | 0.93 | 0.47 | 1.61 | 1.43 | 0.36 | 0.24 | 0.57 | 0.92 | 1.97 | 1.26 | 0.77 |